Home / Health / China Approves First Liquid Frown Line Injectable
China Approves First Liquid Frown Line Injectable
23 Oct
Summary
- First ready-to-use liquid neuromodulator approved in China.
- Relfydess offers fast onset and sustained results up to six months.
- China market shows strong demand for natural, long-lasting results.
The Chinese National Medical Products Administration (NMPA) has granted approval for Relfydess™, marking a significant advancement in the country's aesthetics market. This is the first and only ready-to-use liquid neuromodulator to receive approval in China, designed to temporarily improve moderate-to-severe frown lines in adults.
Developed with PEARL™ Technology, Relfydess offers a novel, complex-free molecule optimized for easy volumetric dosing without reconstitution. Clinical data, including local phase III trials and global READY studies, demonstrated a fast onset of action, with significant improvements in frown lines observed as early as day one.
Results from clinical trials indicate that Relfydess can provide sustained improvements for up to six months in a majority of patients. The product has a favorable safety profile, with predominantly local and expected side effects. Galderma highlights that 88% of Chinese patients prioritize natural-looking results, and 86% seek long-lasting effects up to six months.
This approval expands Galderma's Injectable Aesthetics portfolio in China, one of the world's largest and fastest-growing aesthetics markets. Relfydess is already authorized in over 35 markets globally, reinforcing Galderma's leadership in the Asia-Pacific region.
